Publication: Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts
2
item.page.dc.date.issued
1998-01-01
item.page.dc.type
item.page.dc.identifier.issn
0264410X
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-0031986269
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Vaccine. Vol.16, No.2-3 (1998), 142-149
punsarn.item.page.citation
Anuwat Limsuwan, Vina Churdboonchart, Ronald B. Moss, Worachart Sirawaraporn, Reungpung Sutthent, Buranaj Smutharaks, David Glidden, Richard Trauger, Georgia Theofan, Dennis Carlo Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts. Vaccine. Vol.16, No.2-3 (1998), 142-149. doi:10.1016/S0264-410X(97)88327-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18327
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
The safety and immunogenicity of REMUNE(TM), an HIv-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE(TM) appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE(TM) is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE(TM) to treat HIV-1 infection.